Open-label Study to Assess the Pharmacokinetics of NKTR-118 in Patients with Impaired Hepatic Function

Exclusion Criteria

• - Plasma or blood product donation within 1 month of screening or any blood donation/blood loss greater than 500 mL during the 3 months prior to screening.
• - History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity
• - Known or suspected history of drug/chemical abuse within the past 2 years as judged by the Investigator.
• - Subjects with a history of surgery on the gastrointestinal tract.
• - For patients with hepatic impairment, fluctuating or rapidly deteriorating hepatic function as indicated by clinical and/or laboratory signs of hepatic impairment (e.g. advanced ascites, infection of ascites, fever, or active gastrointestinal bleeding).